Crizanlizumab Use in Recurrent Neurologic Symptoms Attributed to Sickle Cell Disease Induced Moyamoya Syndrome

被引：0
|
作者：
Zik, Chad [1 ]
Alan, Sheinei [1 ]
Ershler, William B. [1 ]
机构：
[1] Inova Schar Canc Inst, Adult Sickle Cell Ctr, Fairfax, VA USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-170745
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：11157 / 11158
页数：2
相关论文
共 50 条
  • [1] Crizanlizumab in sickle cell disease
    Kaur, Kiranveer
    Kennedy, Katie
    Liles, Darla
    PAIN MANAGEMENT, 2023,
  • [2] Crizanlizumab in Sickle Cell Disease
    Ataga, Kenneth I.
    Kutlar, Abdullah
    Kanter, Julie
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (18): : 1796 - 1796
  • [3] Crizanlizumab for pain in sickle cell disease
    Ataga KI
    Kutlar A
    Kanter J
    中华物理医学与康复杂志, 2017, 39 (06) : 432 - 432
  • [4] Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events
    Dobson, SR
    Holden, KR
    Nietert, PJ
    Cure, JK
    Laver, JH
    Disco, D
    Abboud, MR
    BLOOD, 2002, 99 (09) : 3144 - 3150
  • [5] Treatment of Sickle Cell Disease Pain With Crizanlizumab
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (03) : 308 - 308
  • [6] Early Evaluation of the Use of Crizanlizumab in Sickle Cell Disease: A National Alliance of Sickle Cell Centers Study
    Kanter, Julie
    Hellemann, Gerhard
    Cohen, Alice J.
    Manwani, Deepa
    Idowu, Modupe
    Guarino, Stephanie
    Rehman, Sana Saif Ur
    Treadwell, Marsha
    Clay, E. Leila Jerome
    Owusu-Ansah, Amma
    Little, Jane A.
    Desai, Payal
    Madisetti, Mohan
    Lanzkron, Sophie M.
    BLOOD, 2021, 138
  • [7] Neurologic symptoms in a patient with sickle cell disease: when is it not a stroke?
    Taylor, E.
    Revanna, P.
    Jm, Mack
    Mayo, R.
    Cox, C.
    Slate, R.
    Parkey, A.
    Saccente, S.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2025, 369 : S249 - S250
  • [8] A critical evaluation of crizanlizumab for the treatment of sickle cell disease
    Karki, Nabin Raj
    Saunders, Katherine
    Kutlar, Abdullah
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (01) : 5 - 13
  • [9] PHYSIOLOGICAL EFFECTS OF CRIZANLIZUMAB ON SICKLE CELL DISEASE COMPLICATIONS
    Chang, S.
    Idowu, M.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2022, 70 (02) : 670 - 671
  • [10] Crizanlizumab approved in Europe for Prevention of recurrent vaso-occlusive Crises in Sickle Cell Disease
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2021, 48 (01) : 69 - 69
12345